Markus Müller was born in Klagenfurt in 1967 and in 1993 he graduated “sub auspiciis" at the Medical Faculty of the University of Vienna. He then underwent training in departments of emergency medicine, oncology, endocrinology, infectious diseases and chemotherapy, clinical pharmacology, and angiology in Austria, Sweden, and the USA and gained a doctorate in clinical pharmacology (1998) and internal medicine (2001).
In 2004 he qualified as a professor and became Principal of the University Department of Clinical Pharmacology of MedUni Vienna at Vienna General Hospital. He earned an international reputation through his work on developing clinical microdialysis and his expertise in the clinical development of innovative drugs and vaccines. Amongst other things, he was heavily involved in the clinical development of several vaccines against influenza H5N1, influenza H1N1, borreliosis/Lyme disease, and Alzheimer's disease, to name but a few.
In 2014 he was appointed Chairman of the Data Safety Monitoring Board (DSMB) of the WHO Ebola vaccination program (VEBCON). Markus Müller has published more than 200 original papers in the field of internal medicine and clinical pharmacology and has won several prizes; for example the Tanabe Award of the American College of Clinical Pharmacology (ACCP) in recognition of his innovative approaches to clinical pharmacology studies. Until 2011 he was Vice-Rector for Research and since 2015 he is the current Rector of MedUni Vienna.